Lensar's ALLY Adaptive Cataract Treatment System Approved in Europe

Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its distributor network in the EU and expects to place the first ALLY systems with European surgeons in the third quarter of 2024.

“We are thrilled to receive EU MDR certification for ALLY, which marks a significant milestone for Lensar. We believe ALLY’s commercial availability in the EU creates a significant growth opportunity for us, through the ability to provide new capabilities and advanced next-generation laser technology to European surgeons,” Nick Curtis, President and CEO of Lensar, said in a company news release. “European cataract surgeons now have access to a technology that has demonstrated to not only enhance the precision, efficiency and patient satisfaction associated with the procedure, but also to significantly improve practice workflow and economics.”

In its second quarter earnings report released today, Lensar announced that 17 New ALLY systems were placed in the second quarter of 2024—its highest number of placements since launch.

ALLY is the first platform to enable surgeons to perform a laser cataract procedure in a single, sterile environment, according to Lensar. Due to its ergonomic design, speed and features, ALLY is designed to increase both patient and practice efficiencies. The company says ALLY is the first and only cataract laser to use artificial intelligence in the iris registration and surface identification of astigmatism management. The system also automatically determines cataract density, and optimizes fragmentation patterns and energy settings, with the goal of minimizing the overall energy delivered to complete the cataract procedure more efficiently and help contribute to quicker visual recovery and better patient outcomes.